NRBP2 and breast cancer: The Kaplan–Meier analysis of recurrence-free survival (RFS) and overall survival (OS) in all patients and patients with the Luminal A subtype of BC showed that the group with high NRBP2 expression had a better outcome than the group with low NRBP2 expression (Figures 2A–C,E,F).